

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+1.42%
+4.00%
+1.50%
+2.86%
-1.82%
TNGX
Tango Therapeutics I
$7.80
Strengths

Trading below its fair value
Chart
$8.53 (-8.56%)
$6.05 (+28.93%)
$3.24 (+140.74%)
$3.24 (+140.74%)
TNGX has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

TNGX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Trading below its fair value
![]()
TNGX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
TNGX Street view is bullish and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is TNGX current stock price?
What are TNGX stock strengths?
What risks are associated with TNGX stock?
When is TNGX next earnings report?
What is TNGX market cap and volume?
What is TNGX's current Stock IQ?
Should I buy TNGX stock right now?
Is TNGX a Strong Buy right now?
What does a 'Strong Buy' rating mean for TNGX?
What does a 'Strong Sell' rating mean for TNGX?
What factors influence TNGX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+1.42%
+4.00%
+1.50%
+2.86%
-1.82%
TNGX
Tango Therapeutics I
Current Price
$7.80
Stock Insights
Strengths

Trading below its fair value
Chart
$8.53 (-8.56%)
$6.05 (+28.93%)
$3.24 (+140.74%)
$3.24 (+140.74%)
TNGX Analysts Opinion
TNGX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Trading below its fair value
![]()
TNGX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
TNGX Street view is bullish and have negative views on the near-term outlook
TNGX has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels.
TNGX Latest Analysis
Tango Therapeutics Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers - Slideshow.
Thu Oct 23, 2025
Tango Therapeutics Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers Transcript.
Thu Oct 23, 2025
Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial Raises Capital To Fund Advancement. ) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with .As of September 1 2025 179 patients were enrolled across all histologies with 154 at active .94 tumor evaluable patients were enrolled more than 6 months before the efficacy analysis and included regardless of outcome.Across cancer types overall response rate (ORR) was 27% the disease control rate (
Thu Oct 23, 2025
Tango Therapeutics Falls 8% After $225 Mln Financing And Phase 1/2 Data Update . (RTTNews) - Tango Therapeutics Inc. (TNGX) fell 7.97% to $7.97 down $0.69 after announcing the pricing of an underwritten offering and concurrent PIPE expected to raise approximately $225 million.
Thu Oct 23, 2025
Tango Therapeutics Announces $225 Million Financing. BOSTON Oct. 23 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics Inc. (NASDAQ:) a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines announced today the pricing of an underwritten offering of 21023337 shares of its common stock and pre-funded warrants to purchase up to 3226458 shares of its common stock (the Offering). The offering price of each share of common stock is $8.6
Thu Oct 23, 2025
Tango Therapeutics rises on $225M financing.
Thu Oct 23, 2025
Tango Therapeutics stock rises after strong pancreatic cancer trial data.
Thu Oct 23, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
TNGX Stock trends
TNGX Stock performance
TNGX Stock analysis
TNGX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.